ER
ERAS.US Erasca Inc
- Market cap
- USD 5.48B
- P/E
- -
- P/B
- 15.26x
- ROE
- -40.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ERAS.US undervalued?
Graham numberThe Graham number of Erasca Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Erasca Inc fundamental analysis
No fundamental analysis for Erasca Inc yet.
Erasca Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) f…
Full company profileErasca Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Erasca Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -310K | -540K | -829K | -2.64M | -3.73M | -3.81M | -3.11M | - |
| Operating Income | -13.3M | -109M | -125M | -247M | -142M | -180M | -131M | -193M |
| EBITDA | -13.0M | -37.0M | -122M | -240M | -121M | -153M | -121M | -369M |
| Net Income | -12.0M | -102M | -123M | -243M | -125M | -162M | -125M | -372M |
| EPS | -0.13 | -5.47 | -1.29 | -2.49 | -1.04 | -0.69 | -0.44 | -1.08 |
| Balance Sheet | ||||||||
| Total Assets | 55.5M | 125M | 501M | 515M | 395M | 503M | 396M | 999M |
| Total Liabilities | 69.1M | 239M | 44.9M | 103M | 78.6M | 79.0M | 71.0M | 82.2M |
| Shareholders' Equity | -13.6M | -114M | 457M | 412M | 317M | 423M | 325M | 917M |
| Cash & Short-term Investments | 50.4M | 119M | 459M | 436M | 312M | 298M | 276M | 644M |
| Total Debt | 3.69M | 2.99M | 18.8M | 55.1M | 55.9M | 51.9M | 47.1M | 43.4M |
| Cash Flow | ||||||||
| Operating Cash Flow | -10.4M | -32.7M | -79.6M | -103M | -101M | -109M | -95.5M | -117M |
| Capital Expenditure | 597K | 38.7M | 18.9M | 16.6M | 1.78M | 22.6M | 128K | 164K |
| Free Cash Flow | -11.0M | -71.4M | -98.5M | -120M | -103M | -132M | -95.6M | -117M |
| Ratios | ||||||||
| ROE | - | - | -26.9% | -59.0% | -39.5% | -38.2% | -38.3% | -40.6% |
| ROA | -21.7% | -81.4% | -24.5% | -47.2% | -31.6% | -32.2% | -31.4% | -37.2% |
| Debt to Equity | - | - | 0.04x | 0.13x | 0.18x | 0.12x | 0.14x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Erasca Inc dividends
Erasca Inc has not paid dividends in the last 7 fiscal years.
Who owns Erasca Inc
- Insiders 6.71%
- Institutions 93.29%
- Public & others 0.00%
- Shares outstanding 350M
- Free float 256M
Top funds holding ERAS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 10.1M | 2.90% | +3.43% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 8.99M | 2.57% | +2.68% | Oct 2026 |
| American Funds SMALLCAP World A | 6.89M | 1.97% | +903.85% | Sep 2026 |
| iShares Russell 2000 ETF | 5.60M | 1.60% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 3.55M | 1.01% | +3,367.49% | Sep 2026 |
| Fidelity Select Biotechnology | 2.49M | 0.71% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 2.41M | 0.69% | +0.15% | Aug 2026 |
| Vanguard MStar Small Cap Value Index | 2.31M | 0.66% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 2.07M | 0.59% | -0.38% | Oct 2026 |
| American Funds New Economy A | 2.00M | 0.57% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.92M | 0.55% | -0.19% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 1.88M | 0.54% | +19.60% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.58M | 0.45% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.54M | 0.44% | +0.24% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 1.53M | 0.44% | 0.00% | Sep 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 1.52M | 0.44% | 0.00% | Sep 2026 |
| Victory Pioneer Select Mid Cap Growth A | 1.52M | 0.43% | -2.74% | Sep 2026 |
| BGF World Healthscience A2 | 1.52M | 0.43% | +55.49% | Jul 2026 |
| T. Rowe Price New Horizons | 1.35M | 0.39% | -3.91% | Sep 2026 |
| Fidelity Extended Market Index | 1.33M | 0.38% | +0.81% | Sep 2026 |
Top institutions holding ERAS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 25.0M | 7.14% | +1.22% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 21.2M | 6.06% | -0.35% | Jun 2026 |
| BlackRock Inc | 21.2M | 6.05% | +4.98% | Jun 2026 |
| RTW INVESTMENTS, LLC | 17.9M | 5.13% | +11.08% | Jun 2026 |
| VR Adviser, LLC | 17.9M | 5.12% | +9.21% | Jun 2026 |
| State Street Corp | 12.2M | 3.48% | +31.02% | Jun 2026 |
| Logos Global Management LP | 12.2M | 3.47% | +8.97% | Jun 2026 |
| Vanguard Capital Management, LLC | 11.4M | 3.26% | +1.36% | Jun 2026 |
| Siren, L.L.C. | 11.4M | 3.26% | +1.37% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 9.55M | 2.73% | -8.11% | Jun 2026 |
| ARCH VENTURE CORP | 7.09M | 2.03% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 6.50M | 1.86% | +8.43% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 6.27M | 1.79% | +245.53% | Jun 2026 |
| Cormorant Asset Management, LLC | 6.00M | 1.72% | +3.45% | Jun 2026 |
| Affinity Asset Advisors, LLC | 5.25M | 1.50% | -1.87% | Jun 2026 |
| Vivo Capital, LLC | 4.13M | 1.18% | -66.03% | Jun 2026 |
| AllianceBernstein L.P. | 4.12M | 1.18% | +55.72% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.82M | 1.09% | -21.60% | Jun 2026 |
| Bank of America Corp | 3.05M | 0.87% | -0.23% | Jun 2026 |
| FMR Inc | 2.88M | 0.82% | +93.51% | Jun 2026 |
Erasca Inc company profile
- Company name
- Erasca Inc
- Ticker
- ERAS.US
- Exchange
- USA Stocks
- Listed since
- Jul 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Fiscal year end
- December
- Address
- 3115 Merryfield Row, San Diego, CA, United States, 92121
- Phone
- 858 465 6511
- Website
- erasca.com
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Erasca Inc management
10- Dr. Jonathan E. Lim M.D.Co-Founder, Chairman & CEO · born 1972
- Dr. David M. Chacko M.D.CFO & Chief Business Officer · born 1983
- Dr. Michael D. Varney Ph.D.Chairman of Research & Development, Scientific Advisory Board Member and Director · born 1958
- Dr. Shannon R. Morris M.D., Ph.D.Chief Medical Officer · born 1970
- Ms. Alison Tjosvold MilhousSenior Vice President of Accounting · born 1979
- Dr. Robert Shoemaker Ph.D.Chief Scientific Officer · born 1981
- Mr. Ebun S. Garner Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1972
- Dr. Lisa Tesvich-Bonora Ph.D.Chief People Officer
- Mr. Brian L. Baker CPA, M.S.Senior Vice President of Finance · born 1967
- Ms. Chandra D. Lovejoy M.S.Chief Regulatory Affairs Officer · born 1971